Skip to content
Esta página está disponible en españolCambiar →
GestorLensSign up

First Tracks Biotherapeutics (TRAX): which funds own it

Health Care →Data as of Jun 30, 2026 (Q2 2026) · updated on Nov 5, 2026

A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.

Follow TRAX for free
Share

Sections with a free account

7 concentrated managers hold it (+3 vs last quarter) with a median weight of 0.6%.

Who owns First Tracks Biotherapeutics?

Holders reporting more than 5% of the shares to the SEC (Schedules 13D/13G): EcoR1 Capital, 9.1% (13G filed Apr 22, 2026), Chen Yu, 8.3% (13G filed Aug 14, 2026), BlackRock, 7.2% (13G/A filed Oct 27, 2026), Sirenia Capital Management, 7.2% (13G filed Aug 14, 2026) and FMR, 5.9% (13G filed Aug 6, 2026). As of Jun 30, 2026, the largest holders reported on Form 13F were EcoR1 Capital (9.1% of the shares), TCG Crossover Management (8.3%) and FMR (5.9%).

Which institutions hold the most First Tracks Biotherapeutics shares?

Per Form 13F filings as of Jun 30, 2026, as a share of all shares outstanding:

  1. 1. EcoR1 Capital: 9.1%
  2. 2. TCG Crossover Management: 8.3%
  3. 3. FMR: 5.9%
  4. 4. Affinity Asset Advisors: 5.8%
  5. 5. BlackRock: 5.6%
  6. 6. Trails Edge Capital Partners: 4.3%
  7. 7. State Street: 4.3%
  8. 8. Vanguard Capital Management: 4.2%
  9. 9. Jupiter Topco: 3.1%
  10. 10. Vestal Point Capital: 2.9%

How much of First Tracks Biotherapeutics do institutions own?

The 150 institutions that file 13F reported 97.7% of the shares as of Jun 30, 2026.

Sources:13G by EcoR1 Capital (Apr 22, 2026) ↗13G by Chen Yu (Aug 14, 2026) ↗13G/A by BlackRock (Oct 27, 2026) ↗13G by Sirenia Capital Management (Aug 14, 2026) ↗13G by FMR (Aug 6, 2026) ↗All of the company's proxy statements on EDGAR ↗

13F percentages divide the shares each institution reports by the shares outstanding on the cover of the company's latest report before the quarter end (May 12, 2026). Entities of the same group file separately and are not added up. We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.

Concentrated managers
7
All 13F: 150
Consensus
17/100
across 7 concentrated managersRanks by accumulation, portfolio weight and number of managers; it does not say more are buying than selling.
Price at Jun 30, 2026 (per 13F)
$20.12
reported value ÷ shares, not the quote · See current quote ↗

Quarter flow (concentrated managers)

Change in managers: 3 opened · 0 exited = +3 (plus 4 who received it in a spin-off)

Net flow in the quarter: +$79.9M (+4.0 M shares) · bought $79.9M and sold $0Shares concentrated managers added minus those they cut, valued at the 13F quarter-end implied price, not each trade's price. It is a different measure from the change in managers: the two can have opposite signs.

Concentrated managers holding it

Up to 15, sorted by position value. The percentage is the weight in each manager's portfolio.

Largest holders of TRAX (all 13F filers)

The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.

Held by institutions (13F)

Institutions (13F): 97.7% of the shares · top 10: 53.6% · in index firms: 20.6% of the institutional total

Shares reported by the 150 13F filers as of Jun 30, 2026, divided by the shares outstanding on the cover of the company's latest report (May 12, 2026). It is not all institutional ownership: only managers above $100M file a 13F, and it excludes short positions. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. We only publish it where the figure is credible: not for ADRs, companies with more than one share class or stale shares-outstanding data.

Fundamentals

Balance sheet only, for now. TRAX has not yet filed its first annual report (10-K) with the SEC, so there are no 12-month figures (revenue, margins, earnings and cash flow). We show the balance sheet from its latest filing; once the 12-month figures are available, this section fills in automatically.

Balance sheet as of Sep 30, 2026
Cash and equivalents
$156M
Shareholders' equity
$151M

Balance sheet figures the company filed with the SEC (10-Q or 10-K), in dollars. Net debt = total debt − cash − investments; when negative, the company has more cash than debt (net cash). How each figure is calculated

Insiders (Form 4)

Officers and directors who bought (6 m)
0
Amount (6 m)
$0
CEO/CFO bought (12 m)
No

10% owners who bought (6 m): 0

Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.

Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →

Above 5% (13D/13G)

Disclosed stakes, with their amendments. A filing is not always a purchase: there are also reductions and changes of filing entity.

This list may be incomplete: we hold 13D and 13G filings made since Dec 23, 2024. A holder above 5% that has not filed anything since then is not shown here.

  • BlackRock7.2%13G · amendmentfiling ↗Event: Sep 30, 2026 · filed: Oct 27, 2026
  • Chen Yu8.3%13Gfiling ↗Event: Jun 30, 2026 · filed: Aug 14, 2026
  • Sirenia Capital Management7.2%13Gfiling ↗Event: Jun 30, 2026 · filed: Aug 14, 2026

Above 5% over time (13D/13G)

Each holder with its filings in order. History since December 2024.

Flagged material events (8-K)

  • Oct 15, 2026Routinefiling ↗

    Unregistered sale of equity securities (Item 3.02)

    «First Tracks Biotherapeutics Announces $200 Million Private Placement»

  • Apr 20, 2026Routinefiling ↗

    Unregistered sale of equity securities (Item 3.02)

    «First Tracks Biotherapeutics Debuts on Nasdaq to Advance»

  • Apr 20, 2026Routinefiling ↗

    Change in directors or officers (Item 5.02)

    «First Tracks Biotherapeutics Debuts on Nasdaq to Advance»

Alert items the company itself flagged in its 8-K filings with the SEC, most serious first. It is the form's label, with no interpretation from us: Item 5.02 covers routine appointments as well as a chief executive's departure; open the filing. The quoted headline is the original press release's.

All material events (8-K)

Earnings, agreements, financing, management changes and announcements from the last year, with a filter by type and a link to each filing.

Other Health Care stocks in managers' portfolios

Same sector and a similar number of concentrated managers holding them. It is a list to keep exploring, not a recommendation.

All of Health Care →

Follow TRAX for free

If someone reports a 5%+ stake, we email you (if you turn it on). And when you come back, see whether concentrated managers got in or out. No credit card.

Follow TRAX